.Pharmacolibrary.Drugs.ATC.J.J06BD07 .Pharmacolibrary.Drugs.ATC.J.J06BD07| name: | CasirivimabAndImdevimab | |
| ATC code: | J06BD07 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1200 | mg |
| volume of distribution: | 8.1 | L |
| clearance: | 0.14 | L/day |
| other parameters in model implementation | ||
Casirivimab and imdevimab are recombinant human monoclonal antibodies that bind to non-overlapping epitopes of the spike protein of SARS-CoV-2, thereby blocking viral entry into human cells. They are used together as a combination therapy for the treatment and post-exposure prophylaxis of COVID-19. The combination received emergency use authorization during the COVID-19 pandemic.
Pharmacokinetic parameters estimated for healthy adults and COVID-19 patients; the following parameters are representative values from available regulatory and pharmacology reviews.